Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database.

Helland T, Hagen KB, Haugstøyl ME, Kvaløy JT, Lunde S, Lode K, Lind RA, Gripsrud BH, Jonsdottir K, Gjerde J, Bifulco E, Hustad S, Jonassen J, Aas T, Lende TH, Lien EA, Janssen EAM, Søiland H, Mellgren G.

Breast Cancer Res Treat. 2019 Aug;177(1):185-195. doi: 10.1007/s10549-019-05294-w. Epub 2019 May 29.

PMID:
31144152
2.

Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.

Helland T, Henne N, Bifulco E, Naume B, Borgen E, Kristensen VN, Kvaløy JT, Lash TL, Alnæs GIG, van Schaik RH, Janssen EAM, Hustad S, Lien EA, Mellgren G, Søiland H.

Breast Cancer Res. 2017 Nov 28;19(1):125. doi: 10.1186/s13058-017-0916-4.

3.

The active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cells.

Helland T, Gjerde J, Dankel S, Fenne IS, Skartveit L, Drangevåg A, Bozickovic O, Flågeng MH, Søiland H, Mellgren G, Lien EA.

PLoS One. 2015 Apr 13;10(4):e0122339. doi: 10.1371/journal.pone.0122339. eCollection 2015.

4.

Novel inflammatory biomarkers in primary hyperparathyroidism.

Christensen MH, Fenne IS, Nordbø Y, Varhaug JE, Nygård KO, Lien EA, Mellgren G.

Eur J Endocrinol. 2015 Jul;173(1):9-17. doi: 10.1530/EJE-14-1038. Epub 2015 Apr 7.

PMID:
25850829
5.

Estradiol determines the effects of PTH on ERα-dependent transcription in MC3T3-E1 cells.

Christensen MH, Fenne IS, Flågeng MH, Almås B, Lien EA, Mellgren G.

Biochem Biophys Res Commun. 2014 Jul 18;450(1):360-5. doi: 10.1016/j.bbrc.2014.05.109. Epub 2014 Jun 2.

PMID:
24944021
6.

Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment.

Lien EA, Søiland H, Lundgren S, Aas T, Steen VM, Mellgren G, Gjerde J.

Breast Cancer Res Treat. 2013 Sep;141(2):243-8. doi: 10.1007/s10549-013-2677-9. Epub 2013 Sep 1.

7.

cAMP response element-binding protein interacts with and stimulates the proteasomal degradation of the nuclear receptor coactivator GRIP1.

Hoang T, Fenne IS, Madsen A, Bozickovic O, Johannessen M, Bergsvåg M, Lien EA, Stallcup MR, Sagen JV, Moens U, Mellgren G.

Endocrinology. 2013 Apr;154(4):1513-27. doi: 10.1210/en.2012-2049. Epub 2013 Mar 5.

8.

1,25-dihydroxyvitamin D and the vitamin D receptor gene polymorphism Apa1 influence bone mineral density in primary hyperparathyroidism.

Christensen MH, Apalset EM, Nordbø Y, Varhaug JE, Mellgren G, Lien EA.

PLoS One. 2013;8(2):e56019. doi: 10.1371/journal.pone.0056019. Epub 2013 Feb 13.

9.

Breaking away: high fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients.

Søiland H, Hagen KB, Gjerde J, Lende TH, Lien EA.

Acta Oncol. 2013 May;52(4):861-2. doi: 10.3109/0284186X.2012.742963. Epub 2012 Nov 29. No abstract available.

PMID:
23193962
10.

Vitamin B6 status and interferon-γ-mediated immune activation in primary hyperparathyroidism.

Christensen MH, Pedersen EK, Nordbø Y, Varhaug JE, Midttun Ø, Ueland PM, Nygård OK, Mellgren G, Lien EA.

J Intern Med. 2012 Dec;272(6):583-91. doi: 10.1111/j.1365-2796.2012.02570.x. Epub 2012 Aug 5.

11.

Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer.

Moi LL, Flågeng MH, Gjerde J, Madsen A, Røst TH, Gudbrandsen OA, Lien EA, Mellgren G.

BMC Cancer. 2012 Jun 15;12:247. doi: 10.1186/1471-2407-12-247.

12.

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.

Gjerde J, Gandini S, Guerrieri-Gonzaga A, Haugan Moi LL, Aristarco V, Mellgren G, Decensi A, Lien EA.

Breast Cancer Res Treat. 2012 Jul;134(2):693-700. doi: 10.1007/s10549-012-2074-9. Epub 2012 May 5.

13.

Grapefruit juice and licorice increase cortisol availability in patients with Addison's disease.

Methlie P, Husebye EE, Hustad S, Lien EA, Løvås K.

Eur J Endocrinol. 2011 Nov;165(5):761-9. doi: 10.1530/EJE-11-0518. Epub 2011 Sep 6.

PMID:
21896619
14.

Primary hyperparathyroidism influences the expression of inflammatory and metabolic genes in adipose tissue.

Christensen MH, Dankel SN, Nordbø Y, Varhaug JE, Almås B, Lien EA, Mellgren G.

PLoS One. 2011;6(6):e20481. doi: 10.1371/journal.pone.0020481. Epub 2011 Jun 17.

15.

Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer.

DeCensi A, Guerrieri-Gonzaga A, Gandini S, Serrano D, Cazzaniga M, Mora S, Johansson H, Lien EA, Pruneri G, Viale G, Bonanni B.

Ann Oncol. 2011 Mar;22(3):582-7. doi: 10.1093/annonc/mdq427. Epub 2010 Aug 17.

PMID:
20716629
16.

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.

Gjerde J, Geisler J, Lundgren S, Ekse D, Varhaug JE, Mellgren G, Steen VM, Lien EA.

BMC Cancer. 2010 Jun 21;10:313. doi: 10.1186/1471-2407-10-313.

17.

Seasonal and age-related differences in serum 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and parathyroid hormone in patients from Western Norway.

Christensen MH, Lien EA, Hustad S, Almås B.

Scand J Clin Lab Invest. 2010 Jul;70(4):281-6. doi: 10.3109/00365511003797172.

PMID:
20429698
18.

Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.

Haugan Moi LL, Hauglid Flågeng M, Gandini S, Guerrieri-Gonzaga A, Bonanni B, Lazzeroni M, Gjerde J, Lien EA, DeCensi A, Mellgren G.

Clin Cancer Res. 2010 Apr 1;16(7):2176-86. doi: 10.1158/1078-0432.CCR-09-1859. Epub 2010 Mar 23. Erratum in: Clin Cancer Res. 2010 Oct 15;16(20):5087. De Censi, Andrea [corrected to DeCensi, Andrea].

19.

Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.

Bonanni B, Serrano D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Macis D, Cazzaniga M, Luini A, Cassano E, Oldani S, Lien EA, Pelosi G, Decensi A.

Clin Cancer Res. 2009 Nov 15;15(22):7053-60. doi: 10.1158/1078-0432.CCR-09-1354. Epub 2009 Nov 3.

20.

Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors.

Flågeng MH, Moi LL, Dixon JM, Geisler J, Lien EA, Miller WR, Lønning PE, Mellgren G.

Br J Cancer. 2009 Oct 20;101(8):1253-60. doi: 10.1038/sj.bjc.6605324. Epub 2009 Sep 15.

21.

Genotype-guided tamoxifen therapy: time to pause for reflection?

Lash TL, Lien EA, Sørensen HT, Hamilton-Dutoit S.

Lancet Oncol. 2009 Aug;10(8):825-33. doi: 10.1016/S1470-2045(09)70030-0. Review.

22.

Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.

Decensi A, Robertson C, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H, Galimberti V, Cassano E, Moroni SM, Formelli F, Lien EA, Pelosi G, Johnson KA, Bonanni B.

J Clin Oncol. 2009 Aug 10;27(23):3749-56. doi: 10.1200/JCO.2008.19.3797. Epub 2009 Jul 13.

23.

Recruitment of coactivator glucocorticoid receptor interacting protein 1 to an estrogen receptor transcription complex is regulated by the 3',5'-cyclic adenosine 5'-monophosphate-dependent protein kinase.

Fenne IS, Hoang T, Hauglid M, Sagen JV, Lien EA, Mellgren G.

Endocrinology. 2008 Sep;149(9):4336-45. doi: 10.1210/en.2008-0037. Epub 2008 May 22.

PMID:
18499756
24.

Tamoxifen impairs both longitudinal and cortical bone growth in young male rats.

Karimian E, Chagin AS, Gjerde J, Heino T, Lien EA, Ohlsson C, Sävendahl L.

J Bone Miner Res. 2008 Aug;23(8):1267-77. doi: 10.1359/jbmr.080319.

25.

Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.

Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER, Mellgren G, Steen VM, Lien EA.

Ann Oncol. 2008 Jan;19(1):56-61. Epub 2007 Oct 18.

PMID:
17947222
26.

Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study.

Geisler J, Lønning PE, Krag LE, Løkkevik E, Risberg T, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Eide GE, Polli A, di Salle E, Paolini J.

Eur J Cancer. 2006 Nov;42(17):2968-75. Epub 2006 Sep 11.

PMID:
16963261
27.

Pretreatment with tamoxifen does not change acute epirubicin cardiotoxicity in rats.

Schjøtt J, Gjerde J, Kisanga ER, Lien EA.

Basic Clin Pharmacol Toxicol. 2006 Feb;98(2):231-4. No abstract available.

28.

Excretion of hydroxylated metabolites of tamoxifen in human bile and urine.

Kisanga ER, Mellgren G, Lien EA.

Anticancer Res. 2005 Nov-Dec;25(6C):4487-92.

29.

Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry.

Gjerde J, Kisanga ER, Hauglid M, Holm PI, Mellgren G, Lien EA.

J Chromatogr A. 2005 Jul 29;1082(1):6-14.

PMID:
16038189
30.

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.

Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G.

J Clin Oncol. 2005 Aug 1;23(22):5126-37. Epub 2005 Jun 27.

PMID:
15983390
31.

Induction of hepatic drug-metabolising enzymes and tamoxifen metabolite profile in relation to administration route during low-dose treatment in nude rats.

Kisanga ER, Moi LL, Gjerde J, Mellgren G, Lien EA.

J Steroid Biochem Mol Biol. 2005 Apr;94(5):489-98. Epub 2005 Apr 7.

PMID:
15876414
32.

Phenotypic expression of the methylenetetrahydrofolate reductase 677C-->T polymorphism and flavin cofactor availability in thyroid dysfunction.

Hustad S, Nedrebø BG, Ueland PM, Schneede J, Vollset SE, Ulvik A, Lien EA.

Am J Clin Nutr. 2004 Oct;80(4):1050-7.

PMID:
15447919
33.

cAMP-dependent protein kinase regulates ubiquitin-proteasome-mediated degradation and subcellular localization of the nuclear receptor coactivator GRIP1.

Hoang T, Fenne IS, Cook C, Børud B, Bakke M, Lien EA, Mellgren G.

J Biol Chem. 2004 Nov 19;279(47):49120-30. Epub 2004 Sep 3.

34.

Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Lien EA, Ueland PM, Lønning PE.

J Natl Cancer Inst. 2004 Jun 2;96(11):884; author reply 884-5. No abstract available.

PMID:
15173277
35.

Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial.

Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C, Serrano D, Pelosi G, Decensi A, Lien EA.

Clin Cancer Res. 2004 Apr 1;10(7):2336-43.

36.

Betaine as a determinant of postmethionine load total plasma homocysteine before and after B-vitamin supplementation.

Holm PI, Bleie Ø, Ueland PM, Lien EA, Refsum H, Nordrehaug JE, Nygård O.

Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):301-7. Epub 2003 Dec 29.

PMID:
14699020
37.

Homocysteine and its relation to B-vitamins in Graves' disease before and after treatment: effect modification by smoking.

Nedrebø BG, Hustad S, Schneede J, Ueland PM, Vollset SE, Holm PI, Aanderud S, Lien EA.

J Intern Med. 2003 Nov;254(5):504-12.

38.

Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women.

Bonanni B, Johansson H, Gandini S, Guerrieri-Gonzaga A, Sandri MT, Mariette F, Lien EA, Decensi A.

J Thromb Haemost. 2003 Oct;1(10):2149-52.

39.

A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.

Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, Veronesi P, Torrisi R, Cazzaniga M, Mora S, Sandri MT, Pelosi G, Luini A, Goldhirsch A, Lien EA, Veronesi U.

J Natl Cancer Inst. 2003 Jun 4;95(11):779-90.

PMID:
12783932
40.

Characterization of receptor-interacting protein RIP140 in the regulation of SF-1 responsive target genes.

Mellgren G, Børud B, Hoang T, Yri OE, Fladeby C, Lien EA, Lund J.

Mol Cell Endocrinol. 2003 May 30;203(1-2):91-103.

PMID:
12782406
41.

Tamoxifen administration and metabolism in nude mice and nude rats.

Kisanga ER, Gjerde J, Schjøtt J, Mellgren G, Lien EA.

J Steroid Biochem Mol Biol. 2003 Feb;84(2-3):361-7.

PMID:
12711024
43.

Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease.

Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye ES, Lien EA, Aanderud S.

Eur J Endocrinol. 2002 Nov;147(5):583-9.

PMID:
12444889
44.

Delayed diagnosis of osseous blastomycosis in two patients following environmental exposure in nonendemic areas.

Veligandla SR, Hinrichs SH, Rupp ME, Lien EA, Neff JR, Iwen PC.

Am J Clin Pathol. 2002 Oct;118(4):536-41. Review.

PMID:
12375640
45.

Racial/ethnic differences in CD4 T cell count and viral load at presentation for medical care and in follow-up after HIV-1 infection.

Swindells S, Cobos DG, Lee N, Lien EA, Fitzgerald AP, Pauls JS, Anderson JR.

AIDS. 2002 Sep 6;16(13):1832-4.

PMID:
12218399
46.

[Thyrotoxic periodic paralysis--an unusual complication of hyperthyroidism].

Mellgren G, Holm PI, Lien EA, Bleskestad IH, Aanderud S, Bindoff L.

Tidsskr Nor Laegeforen. 2002 Apr 20;122(10):1029-31. Norwegian.

47.

Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women.

Bonanni B, Johansson H, Gandini S, Guerrieri-Gonzaga A, Torrisi R, Sandri MT, Cazzaniga M, Mora S, Robertson C, Lien EA, Decensi A.

Breast Cancer Res Treat. 2001 Sep;69(1):21-7.

PMID:
11759825
48.

Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial.

Guerrieri-Gonzaga A, Baglietto L, Johansson H, Bonanni B, Robertson C, Sandri MT, Canigiula L, Lampreda C, Diani S, Lien EA, Decensi A.

Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):967-70.

49.

Plasma total homocysteine in hyper- and hypothyroid patients before and during 12 months of treatment.

Nedrebø BG, Nygård O, Ueland PM, Lien EA.

Clin Chem. 2001 Sep;47(9):1738-41. No abstract available.

50.

Smoking, folate and methylenetetrahydrofolate reductase status as interactive determinants of adenomatous and hyperplastic polyps of colorectum.

Ulvik A, Evensen ET, Lien EA, Hoff G, Vollset SE, Majak BM, Ueland PM.

Am J Med Genet. 2001 Jul 1;101(3):246-54.

PMID:
11424140

Supplemental Content

Support Center